Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
Go back to Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma| Pfizer Inc. (NYSE: PFE) | Delayed: 25.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $25.08 | 52 Week Low | $28.25 | |||
| Day High | $25.08 | P/E | 15.20 | |||
| Day Low | $25.08 | EPS | $1.65 | |||
| Volume | 145,412 | |||||
